ADHD clinical guideline videos - ADHD Institute.com

Guidelines are not written in stone; clinical evidence accumulates and evidence-based practice recommendations are made. International and European guidelines for attention-deficit hyperactivity disorder (ADHD) and hyperkinetic disorder (HKD) continue to be updated as new clinical data emerges. Updated recommendations are designed to improve the diagnosis and management of ADHD in clinical practice.

At Meeting of Minds X (Madrid, Spain, 17-18 April, 2018), a scientific forum initiated, organised and funded by Shire, a panel of eminent ADHD specialists (Professor Philip Asherson, Professor Patrick Bolton, Professor Tobias Banaschewski, Professor David Coghill, Professor David Daley, Dr Martin Gignac, Dr Bruno Nazar and Professor Luis Rohde) discussed clinical guidelines in detail during a discussion forum moderated by Dr Duncan Manders entitled “Clinical guidelines for the diagnosis and management of ADHD in children, adolescents and adults: updates, similarities and differences”. Please select the videos below to view a summary of the discussions.

Overview of approaches to guideline development

Similarities and differences between the guidelines

Non-pharmacological versus pharmacological treatments in guidelines

How is evidence rated when deciding how to incorporate it into a guideline?

What is the purpose of guidelines?

Are people following the guidelines?

Why is there variability in the implementation of the guidelines?

The views represented in these videos are those of the individuals in the discussion panel, who have all been involved in the development of guidelines in their countries. Their views and opinions do not represent the views of Shire, and the individuals are not speaking on behalf of any organisation that may be depicted in the discussions. Guidelines discussed were selected by the experts, and this is not intended to be a comprehensive review of ADHD guidelines. The original discussion has been edited by Shire for ease of viewing.

Date of preparation: July 2018; Job code: C-ANPROM/INT//3100

ADHD Clinical Guidelines

Several guidelines for the diagnosis and management of ADHD have been published; these include the CADDRA, DGPPN, NICE & SIGN guidelines

Overview of approaches to guideline development

Similarities and differences between the guidelines

Non-pharmacological versus pharmacological treatments in guidelines

How is evidence rated when deciding how to incorporate it into a guideline?

What is the purpose of guidelines?

Are people following the guidelines?

Why is there variability in the implementation of the guidelines?

Filter content by:

Missed the Adult ADHD and comorbid anxiety disorders webinar?

Participate in the knowledge checks and hear the Q&A panel discussion

Missed the Adult ADHD and comorbid major depressive disorder webinar?

Participate in the knowledge checks and hear the Q&A panel discussion

Missed the Adult ADHD and comorbid bipolar disorder webinar?

Participate in the knowledge checks and hear the Q&A panel discussion

Healthcare professional registration

Registration gives the benefit of site update e-mails and additional information from Shire on new education materials and events.

ADHD: improving visibility in adults

Overview of the impact of ADHD in adulthood and opportunities to improve recognition and management

How do current guidelines measure up in managing ADHD?

Symptoms of ADHD

ADHD is defined by symptoms of inattention, hyperactivity and impulsivity. Classification depends on the relative contribution of each feature

Patient-centred management: every patient is different with unique needs – a Spanish perspective. Part 1: Evaluation

Patient-centred management: every patient is different with unique needs – a Spanish perspective. Part 2: Treatment plans for children and adolescents

ADHD diagnosis and screening in adults

Clinical assessment using the ASRS v1.2 Screening Scale

When choosing the most appropriate treatment for your patient with ADHD, what consideration do you give regarding the flexibility of dosing? | Professor Peter Hill

Interactive module: ADHD across the ages

When choosing a treatment, how big a consideration are the ADHD patients’ co-morbid conditions or co-morbid symptoms? How do you decide which symptoms to treat?